Edit
Shanghai Yingli Pharmaceutical Co., Ltd.
http://www.yl-pharma.com/en/Last activity: 01.04.2025
Active
Investors 1
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
Mentions in press and media 5
| Date | Title | Description |
| 01.04.2025 | Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory... | SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today t... |
| 11.12.2023 | Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Mee... | Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd... |
| 09.11.2022 | Yingli Pharma Announces NMPA Approval of New Anti-cancer Drug Linperlisib | The first highly selective PI3Kδ inhibitor in China SHANGHAI, CHINA – Media OutReach – 9 November 2022 – Shanghai Yingli Pharmaceutical Co., Ltd. (the “Company” or “Yingli Pharma“) is pleased to announce that linperlisib, trade name因他瑞®, a ... |
| 11.06.2021 | Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2... | SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical... |
| 04.06.2021 | Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annu... | Clinical trial data will be updated in three presentations on lead drug candidates Linperlisib, a potent oral PI3Kδ inhibitor, demonstrated robust clinical activity with 70% ORR in relapsed or refractory Peripheral T-cell Lymphoma Linperlis... |